Forbes October 14, 2023
Cancer patients’ high out-of-pocket cost burden is sometimes described as “financial toxicity.” Already faced with a life-threatening illness, financial toxicity can cause economic pain but also further mental and emotional anguish for U.S. patients. The Inflation Reduction Act’s cap of $2,000 on annual out-of-pocket spending on outpatient drugs will help alleviate the issue, as may Medicare drug price negotiations for a limited number of high-cost pharmaceuticals.
Historically, as anti-cancer drugs have gained regulatory approvals, such as PD-1 and PD-L1 checkpoint inhibitors, price competition has not been a factor. This is unusual, given how relatively crowded various oncology indications targeted by checkpoint inhibitors have become: From breast, renal and colorectal cancer, to melanoma and non-small cell lung cancer.
Several companies, including...
Today's Sponsors
Today's Sponsor